Reduction of Myocardial Fibrosis and Improvement of Diastolic Function with Urolithin A Administration
Activation of Mitophagy for the Clearance of Damaged Mitochondria

The Gwangju Institute of Science and Technology (GIST) announced on August 3, 2026, that a joint research team led by Professor Oh Changmyoung from the Department of Biomedical Science and Engineering at GIST and Professor Park Sangwook from the Chonnam National University School of Dentistry has identified the mechanism by which urolithin A, a natural metabolite produced by gut microbiota, inhibits the progression of Heart Failure with Preserved Ejection Fraction (HFpEF).

The effect of Urolithin A on improving heart failure with preserved ejection fraction (HFpEF). Provided by GIST

The effect of Urolithin A on improving heart failure with preserved ejection fraction (HFpEF). Provided by GIST

View original image

Heart failure is a disease in which abnormal contraction or relaxation of the heart prevents sufficient blood supply throughout the body. Heart Failure with Preserved Ejection Fraction, which accounts for about half of all heart failure cases, is a condition where the heart’s ability to pump blood remains nearly normal, but the cardiac muscle becomes stiff and cannot receive blood efficiently. This type is closely linked to metabolic diseases such as obesity, diabetes, and hypertension, and due to its complex causes, there is still a shortage of fundamental treatments.


The research team focused on the fact that, as HFpEF progresses, mitochondria—the organelles in heart cells responsible for energy production—become damaged. Their clearance function becomes impaired, leading to the accumulation of damaged mitochondria.


When urolithin A—produced during the metabolism of foods such as pomegranate, strawberries, and walnuts by gut microbiota—was administered to a mouse model of heart failure, results showed that: ▲ diastolic function of the heart, which had been reduced, improved by approximately 32%; ▲ cardiac hypertrophy decreased by about 9.4%; and ▲ myocardial fibrosis decreased by roughly 42% compared to the untreated group. Additionally, in myocardial cells derived from human induced pluripotent stem cells, expression of fibrosis-related genes was also reduced.


Analysis of the mechanism revealed that urolithin A activates mitophagy, the cellular process for selectively removing damaged mitochondria. In doing so, it restored the structure and energy-producing function of mitochondria.


Furthermore, the study demonstrated a combined effect: urolithin A altered the composition of gut microbiota involved in the production of ceramide—a lipid that can trigger inflammation when excessively accumulated—thereby lowering ceramide levels in the blood.


Professor Oh Changmyoung of GIST stated, “Urolithin A, a gut microbiota-derived metabolite, promotes the removal of damaged mitochondria and regulates both gut microbiota and lipid metabolism, thus alleviating Heart Failure with Preserved Ejection Fraction. We expect this will pave the way for broadening treatment possibilities for a condition that has lacked fundamental therapeutic options.”



Supported by the Ministry of Science and ICT and the Ministry of Health and Welfare, the findings of this study were published online in the international journal Experimental & Molecular Medicine (EMM) on July 10, 2026.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing